Chemomab Therapeutics (CMMB) Liabilities and Shareholders Equity (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $13.8 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 18.58% year-over-year to $13.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $50.1 million (down 28.81% YoY) and the FY2025 annual result came in at $13.8 million, down 18.58% from the prior year.
• Liabilities and Shareholders Equity improved to $13.8 million in Q4 2025, from $12.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $70.5 million in Q2 2021 to a low of $11.1 million in Q2 2025.
• A 5-year average of $35.2 million and a median of $26.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 777.1% — and 2023, when it tumbled 53.37%.
• Tracing CMMB's Liabilities and Shareholders Equity over 5 years: stood at $64.4 million in 2021, then tumbled by 33.08% to $43.1 million in 2022, then slumped by 48.56% to $22.2 million in 2023, then fell by 23.42% to $17.0 million in 2024, then fell by 18.58% to $13.8 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $13.8 million (Q4 2025), $12.4 million (Q3 2025), and $11.1 million (Q2 2025), per Business Quant data.